The solution uses Tobin trailers fitted with PHCbi's ultra-low temperature freezers to ensure that the vaccine is maintained at the correct temperature throughout transit.
Following the announcement last week that Pfizer and partner, BioNTech, had submitted an application to the Food and Drug Administration for approval of their coronavirus vaccine, there have been ongoing discussions about proposed distribution models capable of sustaining the -70°C temperature required to maintain efficacy.
One of the most talked-about solutions is the use of a special cooler, or "thermal shipper," with real-time GPS and thermal monitoring that can maintain deep-freeze vaccine storage for 10 days if left unopened.
While in theory this modality represents a potential distribution solution, it is one fraught with potential for failure. Dry ice is difficult to handle, limited in supply, and has an 18-24-hour half-life.
Should the thermal shipper fail or be compromised, that leaves a window of 18-24 hours from point of origin, to allow for transit to the airport, departure, flight time, arrival at destination, offload, splitting of pallets, and loading to individual trucks to drive to sites administering vaccinations.
Moreover, mRNA by nature, comes with its own inherent handling challenges, and the fragile thermal sensors used in this type of packaging could provide inconsistent and unreliable readings.
All of this is cause for concern, before even addressing the considerable challenge posed by specialized staffing requirements to handle these shipments on the scale that would be required.
The Tobin Scientific team and PHC Corp. of North America (formerly Panasonic Healthcare) have collaborated to jointly develop a distribution solution that they believe is far more reliable.
The solution uses local, regionalized freezer-to-freezer delivery routes on Tobin's specialized, back-up generator-powered and redundant, temperature-controlled trailers.
The trailer units are outfitted with 220v electrical plugs for PHCbi brand freezers to ensure temperature continuity.
Tobin's trailers utilize their patented IQ/OQ cGMP/cGLP calibrated temperature monitoring systems with real-time, live readings recorded locally, in-cab, and transmitted over cell service.
With each selected PHCbi brand freezer able to hold approximately 140,000 doses, this would put trailer capacity at 1m doses across the entire fleet of specialized trailers.
Regional distribution routes will be able to dispatch from Tobin's scalable biorepository, strategically located 20 miles outside of Boston and 25 minutes from Logan airport.
Daily routes to and from Logan would receive pallet loads of vaccine for storage at the Tobin biorepository, ready for redistribution on the daily routes.
Since 1966, PHC Corp. of North America, located in Wood Dale, Illinois, has in laboratory equipment for the biopharmaceutical, life sciences, academic, healthcare, and government markets.
Product lines under the PHCbi brand include the space saving and energy efficient VIP ECO, TwinGuard, and VIP Series ultra-low temperature freezers, cryogenic, and biomedical freezers, pharmacy and high-performance refrigerators, cell culture CO2 and multi-gas incubators, cell processing work stations, and Drosophila/plant growth chambers.
PHC Corp. of North America is a subsidiary of PHC Holdings Corp., Tokyo, Japan, which is a global healthcare company that develops, manufactures, sells, and services solutions across diabetes management, diagnostics and life sciences, as well as providing healthcare services.
Tobin Scientific is a single-source provider of life science laboratory relocation, is a division of Tobin and Sons Moving and Storage based in Beverly Massachusetts.
The company holds patents and specializes in frozen biological and cryogenic transportation, repository, and temperature-controlled storage.
Founded in 1960, Tobin and Sons Moving and Storage is consistently ranked among the top five largest moving and storage companies in the Boston area.
Nanomi BV to acquire ophthalmology specialist VISUfarma BV
AstraZeneca launches online platform to expand patient access to medications
Avant Technologies enters joint venture to advance stem cell-based diabetes treatments
Innovent and Ollin report progress in development of OLN324 (IBI324)
Alteogen secures European Commission approval for aflibercept biosimilar EYLUXVI
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Ascletis presents ASC30 study results at EASD Annual Meeting
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Renalytix signs collaboration agreement with Tempus AI to expand KidneyIntelX.dkd access
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Novo Nordisk to streamline operations and reinvest in diabetes and obesity growth
NICE endorses AOTI's TWO2 therapy for diabetic foot ulcers
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli